Latest / WTR Small-Cap Spotlight
Natural MedTech: Why the Psychedelic Opportunity Starts With Manufacturing
Send us Fan Mail
In this episode, Natural MedTech CEO and Co-Founder Luke McFarlane joins WTR healthcare analyst Robert Sassoon and Shawn Severson to discuss the company's biosynthetic psilocybin manufacturing platform and its position within Australia's evolving psychedelic medicine landscape. The conversation covers the authorized prescriber pathway, including adoption trends, treatment costs, regulatory developments, and early insurer engagement. McFarlane walks through NMT's proprietary biosynthesis platform, its competitive advantages in cost and purity, the ongoing Series A raise, and…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.